Daptomycin in the Treatment of Bacteremia

American Journal of Medicine

Volumn 120, Issue 10 SUPPL. 1, 2007, Pages

  Sakoulas, George ^a   Golan, Yoav ^b   Lamp, Kenneth C ^c   Friedrich, Lawrence V ^c   Russo, Rene ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Coagulase negative staphylococci; Daptomycin; Gram positive bacteremia; Methicillin resistant Staphylococcus aureus; Renal impairment; Vancomycin resistant enterococci

Indexed keywords

CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; LINEZOLID; METRONIDAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CATHETER INFECTION; CHRONIC KIDNEY FAILURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG INFORMATION; DRUG RESEARCH; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; REGISTER; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 34648828527     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.012     Document Type: Article

References (21)

1. Linden P.K. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med 104 (1998) 24S-33S
2. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., and Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004) 309-317
3. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2003) 53-59
4. Bhavnani S.M., Drake J.A., Forrest A., et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 36 (2000) 145-158
5. Lodise T.P., McKinnon P.S., Tam V.H., and Rybak M.J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis 34 (2002) 922-929
6. DiazGranados C.A., and Jernigan J.A. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 191 (2005) 588-595
7. Cosgrove S.E., Qi Y., Kaye K.S., Harbart S., Karchmer A.W., and Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
8. Smith T.L., Pearson M.L., Wilcox K.R., et al., Glycopeptide-Intermediate Staphylococcus aureus Working Group. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 (1999) 493-501
9. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 42 suppl 1 (2006) S25-S34
10. Sakoulas G., Moise-Broder P.A., Schentag J., Forrest A., Moellering Jr. R.C., and Eliopoulos G.M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 42 (2004) 2398-2402
11. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 42 suppl 1 (2006) S13-S24
12. Rhee K.Y., Gardiner D.F., and Charles M. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis 40 (2005) 1705-1706
13. Kapadia M., Coyle E., Prince R., and Rolston K. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at the 45th Annual Meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) (2005), American Society for Microbiology, Washington, DC 168 Abstract E-807
14. Fowler Jr. V.G., Boucher H.W., Corey R., et al., S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355 (2006) 653-665
15. Rolston K.V.I., Segreti J.A., Lamp K.C., and Friedrich L.V. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med 120 10A (2007) S4-S5
16. Fowler Jr. V.G., Miro J.M., Hoen B., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021
17. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
18. Cubicin (daptomycin for injection). [prescribing information] (2006), Cubist Pharmaceuticals, Inc, Lexington, MA
19. Segreti J.A., Crank C.W., and Finney M.S. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 26 (2006) 347-352
20. Furuya E.Y., Kubin C., Yin M., Lowy F., Della-Latta P., and Hammer S. Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia. [abstract K-2116]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) (2005), American Society for Microbiology, Washington, DC 379
21. Okoye O.P., and Mushatt D. Daptomycin: efficacy and safety of use in treatment of gram-positive infections. Presented at the 41st Annual Meeting Infectious Diseases Society of America (IDSA) (2005), Infectious Diseases Society of America, Alexandria, VA 121